The last two decades have witnessed substantial advances in identifying synaptic plasticity
responsible for behavioral changes in animal models of substance use disorder. We have …

Metabotropic glutamate (mGlu) receptors, a family of G-protein-coupled receptors, have
been identified as novel therapeutic targets based on extensive research supporting their …

Use of prescription opioids, particularly oxycodone, is an initiating factor driving the current
opioid epidemic. There are several challenges with modelling oxycodone abuse. First …

Cue-induced drug craving and seeking progressively increases during abstinence. This
“incubation of drug craving” phenomenon has been observed in both laboratory animals …

Cue-induced cocaine craving progressively intensifies (incubates) after withdrawal from
cocaine self-administration in rats and humans. In rats, the expression of incubation …

Many studies have demonstrated that negative allosteric modulators (NAM) of metabotropic
glutamate receptor 5 (mGlu5) reduce cocaine and methamphetamine seeking in extinction …

Dopamine system deficiencies and associated behavioral phenotypes may be a critical
barrier to success in treating stimulant use disorders. Similarities in dopamine dysfunction …

Relapse is a major problem in treating methamphetamine use disorder.“Incubation of
craving” during abstinence is a rat model for persistence of vulnerability to craving and …

A progressive increase in drug craving following drug exposure is an important trigger of
relapse. CircularRNAs (CircRNAs), key regulators of gene expression, play an important …

Relapse to drug use is often preceded by drug craving. Clinical observations in the 1980s
led clinical investigators to postulate that cue-induced cocaine craving may increase during …